Catalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for KT-621 in Asthma. The expected timing is based on the latest available company guidance and may change.
BREADTH trial. 2/27/25- Initiate trial in Q1 2026. 11/04/25:- BREADTH Ph2b asthma trial remains on track to initiate in Q1 2026. 01/29/26:- BREADTH Ph2b asthma trial initiated dosing; data in Late-2027. 02/27/26:- BREADTH Ph2b asthma trial dosing ongoing; 264 patients over 12 weeks; FEV1 primary endpoint; data Late-2027. 04/13/26:- FDA Fast Track granted for eosinophilic asthma; BREADTH Ph2b data expected Late-2027. 04/30/26:- BREADTH Phase 2b asthma program to feature oral at ATS May 2026; data still expected Late-2027. 08/05/26:- BREADTH enrollment ongoing. Ph2b asthma data expected Late-2027.
Verification
Confirm timing and program details against the company announcement or filing.